The science of drug development is only as strong as the evidence behind it. In women’s health, that evidence has long been limited in scope.
For decades, women were significantly underrepresented in clinical trials. Recent years have seen improvement, but there are lingering gaps in our collective understanding of how therapies work across sexes, life stages, health conditions and care settings.
This is partly because the design and execution of clinical trials have sometimes overlooked the unique factors that influence women’s health, such as hormonal fluctuations, caregiving roles and health conditions specific to women.
Check out the rest of the feature here
